All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
MMF dose optimization for GvHD prophylaxis in UCBT
Results from a retrospective study examining optimal mycophenolate mofetil (MMF) dosing for graft-versus-host disease (GvHD) prophylaxis in patients with non-remission myeloid malignancies receiving umbilical cord blood transplantation (UCBT; N = 574) were recently published in Transplantation and Cellular Therapy by Yamamoto et al.
Key data: High-dose MMF (≥23 mg/kg/day) impaired engraftment and increased early non-relapse mortality (NRM) compared with lower doses. Early NRM was primarily due to bacterial infections in the MMF-High group, with Day 28 NRM rates of 12.4% (MMF-High), 2.1% (MMF-Low; <17 mg/kg/day), and 4.7% (MMF-Int; MMF 17–23 mg/kg/day) (p = 0.002). No significant difference in relapse or acute GvHD across MMF dose groups was observed.
Key learning: Careful optimization of MMF dosing may improve early transplant outcomes in patients undergoing UCBT for advanced myeloid malignancies, with high-dose immunosuppression associated with impaired engraftment and risk for early NRM.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?
